Patents by Inventor Marcio Chedid

Marcio Chedid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20230279098
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 7, 2023
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20230279094
    Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer’s Disease or a tauopathy disease.
    Type: Application
    Filed: October 27, 2022
    Publication date: September 7, 2023
    Inventors: Marcio Chedid, Adam S. Fleisher, Megan Brittany Lannan, Albert Lo, Mark Mintun, Victor H. Obungu, Sarah Elisabeth Raines, John Randall Sims, II, Andrew Dixon Skora, Robin Elizabeth Walsh, Elizabeth Anne West, Ming Ye
  • Antibodies to IL-34
    Patent number: 11649280
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • Antibodies that bind TGF-Alpha and Epiregulin for use in the treatment of pain
    Publication number: 20210403547
    Abstract: The present invention provides for therapeutic use of antibodies that bind human TGF-alpha and human Epiregulin in the treatment of chronic pain, and in particular chronic osteoarthritis pain, chronic diabetic neuropathy pain, or chronic low back pain.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 30, 2021
    Inventors: Marcio Chedid, Josef G. Heuer
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20210363232
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 25, 2021
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
    Patent number: 9624218
    Abstract: Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Hisham Omer Eissa, Thomas Albert Engler, Kelly Wayne Furness, Kenneth B. Rank, Timothy Andrew Woods, Aaron D. Wrobleski
  • PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS
    Publication number: 20160251348
    Abstract: Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).
    Type: Application
    Filed: October 29, 2014
    Publication date: September 1, 2016
    Inventors: Marcio CHEDID, Hisham Omer EISSA, Thomas Albert ENGLER, Kelly Wayne FURNESS, Kenneth B. RANK, Timothy Andrew WOODS, Aaron D. WROBLESKI
  • Hematopoietic neoplasm chemotherapy
    Patent number: 9044487
    Abstract: A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: June 2, 2015
    Assignee: Eli Lilly and Company
    Inventor: Marcio Chedid
  • HEMATOPOIETIC NEOPLASM CHEMOTHERAPY
    Publication number: 20140235621
    Abstract: A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: Eli Lilly and Company
    Inventor: Marcio Chedid
  • Hematopoietic neoplasm chemotherapy
    Patent number: 8802668
    Abstract: A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: August 12, 2014
    Assignee: Eli Lilly and Company
    Inventor: Marcio Chedid
  • Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine
    Patent number: 8648063
    Abstract: An improved method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions useful for the method and a process for preparing said compositions.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: February 11, 2014
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Thomas Albert Engler
  • Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-A] pyridine-3-yl-2,5-Dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine
    Patent number: 8318713
    Abstract: A method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions comprising 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-IH-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine, useful for the method and a process for preparing said compositions.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Thomas Albert Engler
  • DKK-1 antibodies
    Patent number: 8148498
    Abstract: The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: April 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Ryan James Darling, Rachelle Jeanette Galvin, Barbara Anne Swanson
  • HEMATOPOIETIC NEOPLASM CHEMOTHERAPY
    Publication number: 20100261712
    Abstract: A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 14, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventor: Marcio Chedid
  • DKK-1 ANTIBODIES
    Publication number: 20100260754
    Abstract: The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.
    Type: Application
    Filed: April 6, 2010
    Publication date: October 14, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Marcio CHEDID, Ryan James DARLING, Rachelle Jeanette GALVIN, Barbara Anne Swanson
  • POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE
    Publication number: 20100166884
    Abstract: A method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions comprising 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-IH-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine, useful for the method and a process for preparing said compositions.
    Type: Application
    Filed: June 20, 2008
    Publication date: July 1, 2010
    Inventors: Aktham Aburub, Marcio Chedid, Thomas Albert Engler, Venkatraghavan Vasudevan